Tracking Residual Disease in Myeloma With Flow Cytometry

Flow cytometry differentiates normal from neoplastic plasma cells.

Normal plasma cells express CD19, CD38; neoplastic forms often do not.

MRD testing is influenced by persistent plasma cells post-therapy.

Anti-CD38 treatment requires additional markers for detection.

Standardized panels enhance accuracy in differentiating cell types.

MRD negativity is included in response criteria by the International Myeloma Working Group.